CIK 0000064803 · Large accelerated filer
CVS HEALTH Corp
Sign in to watch- Ticker
- CVS
- Exchange
- NYSE
- Industry
- Retail-Drug Stores and Proprietary Stores
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 050494040
- Phone
- 4017651500
- Business address
- ONE CVS DR., WOONSOCKET, RI, 02895
- Former names
- CVS CAREMARK CORP, CVS/CAREMARK CORP, CVS CORP, MELVILLE CORP
- Open-market buys, last 90 days
- $2,001,315
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$2,001,315. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-21 | ROBBINS LARRY Director | Sale | −370,462 | $93.45 | $34.6M | 4,824,799 |
| 2026-05-20 | ROBBINS LARRY Director | Sale | −797,628 | $93.48 | $74.6M | 5,415,633 |
| 2026-05-20 | ROBBINS LARRY Director | Sale | −152,691 | $94.81 | $14.5M | 5,262,942 |
| 2026-05-20 | ROBBINS LARRY Director | Sale | −66,881 | $95.67 | $6.4M | 5,196,061 |
| 2026-05-20 | ROBBINS LARRY Director | Sale | −800 | $96.28 | $77K | 5,195,261 |
| 2026-05-19 | ROBBINS LARRY Director | Sale | −1,983,387 | $94.45 | $187.3M | 6,213,412 |
| 2026-05-19 | ROBBINS LARRY Director | Sale | −151 | $95.18 | $14K | 6,213,261 |
| 2026-05-08 | Mandadi Tilak EVP, Chief Exp & Tech Officer | Sale | −69,551 | $89.58 | $6.2M | 10,133 |
| 2025-08-20 | Finucane Anne A. Director | Sale | −7,500 | $71.02 | $533K | 22,156 |
| 2025-05-06 | ROBBINS LARRY Director | Sale | −150,000 | $66.67 | $10.0M | 8,196,799 |
| 2025-05-05 | ROBBINS LARRY Director | Sale | −1,226,933 | $67.37 | $82.7M | 8,443,798 |
| 2025-05-05 | ROBBINS LARRY Director | Sale | −96,999 | $67.99 | $6.6M | 8,346,799 |
| 2025-05-02 | ROBBINS LARRY Director | Sale | −1,679,736 | $67.39 | $113.2M | 10,267,063 |
| 2025-05-02 | ROBBINS LARRY Director | Sale | −222,556 | $68.38 | $15.2M | 10,044,507 |
| 2025-05-02 | ROBBINS LARRY Director | Sale | −373,776 | $69.66 | $26.0M | 9,670,731 |
| 2025-03-05 | Clark James David SVP, Cont & Chief Acct Officer | Sale | −7,513 | $66.35 | $498K | 8,394 |
| 2024-02-16 | Shah Prem S EVP and Pres-Pharm, Consumer W | Sale | −29,473 | $76.95 | $2.3M | 39,764.76 |
| 2023-08-03 | Clark James David SVP, Cont & Chief Acct Officer | Sale | −2,631.26 | $74.79 | $197K | 27,826 |
| 2023-08-03 | Clark James David SVP, Cont & Chief Acct Officer | Sale | −23,128 | $74.94 | $1.7M | 4,698 |
| 2022-12-15 | Moriarty Thomas M EVP & General Counsel | Sale | −100,976 | $98.40 | $9.9M | 608,129.02 |
Page 1 of 2 · 21 trades